ArticleThe American journal of gastroenterology2022
Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial.
Article in The American journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03982264 (Cap Endoscopic Mucosal Resection), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cap Endoscopic Mucosal Resection(EMR-C) Versus Endoscopic Submucosal Dissection(ESD) for Treatment of Rectal Neuroendocrine Tumor(NET) Less Than 10mm
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Is salvage treatment necessary after incomplete resection of rectal neuroendocrine tumors: A systematic review and meta-analysis.World journal of gastroenterology · 2026Pooled it
- Traction-assisted endoscopic submucosal resection (TA-ESD) for rectal neuroendocrine tumors: a randomized multi-center trial.Surgical endoscopy · 2025Trial
- Therapeutic efficacy evaluation of the injection mucosa knife in endoscopic submucosal dissection for rectal neuroendocrine tumors.Translational cancer research · 2026Article
- Efficacy and Safety of Modified Double-snare-assisted Endoscopic Mucosal Resection for Small Rectal Neuroendocrine Tumours: A Preliminary Study.Endoscopy international open · 2026Article
- Efficacy, Safety and Oncological Outcomes of Minimally Invasive Approaches (EMR, ESD and TAMIS) for Early Rectal Tumors: A Systematic Review and Meta-Analysis.Medical devices (Auckland, N.Z.) · 2026Review
- Safety and Efficacy of Simplified EMR Versus ESD for Rectal Neuroendocrine Tumors ≤ 10 Mm: A Retrospective Cohort Study.Journal of clinical medicine · 2025Article
- Current status of endoscopic resection for small rectal neuroendocrine tumors.World journal of gastroenterology · 2025Review
- Endoscopic full-thickness resection: A definitive solution for local complete resection of small rectal neuroendocrine neoplasms.World journal of gastroenterology · 2025Article
- Comparison of endoscopic submucosal dissection and modified endoscopic mucosal resection for rectal neuroendocrine tumors.Scientific reports · 2025Article
- Endoscopic intermuscular dissection for management of 10- to 20-mm rectal neuroendocrine tumors: Pilot study (with video).Endoscopy international open · 2025Article
- The safety and feasibility of a novel cap-assisted endoscopic resection device for rectal tissue resection: a pilot study (with videos).Gastroenterology report · 2025Article
- Comparison of clinicopathological characteristics and survival outcomes between solitary and multiple rectal neuroendocrine tumors: a propensity score-matched study.Frontiers in oncology · 2025Article
- An Update on the Management of Rectal Neuroendocrine Neoplasms.Current treatment options in oncology · 2024Review
- Effective utilization of polypectomy in endoscopic salvage treatment of rectal neuroendocrine tumors: a retrospective cohort study.Annals of surgical treatment and research · 2024Article
- Review
- Efficacy of endoscopic submucosal resection with a ligation device for small rectal neuroendocrine tumor: study protocol of a multicenter open-label randomized control trial (BANDIT trial).BMC gastroenterology · 2024Article
- A novel cap-assisted endoscopic resection device for resection of a rectal lesion in an in vitro pig model.Endoscopy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough recent guidelines recommend endoscopic resection of rectal neuroendocrine tumors (NET) ≤10 mm, there is no consensus on which endoscopic modality should be performed. We aimed to compare the safety and efficacy of modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic submucosal dissection (ESD) methods for the treatment of rectal NET ≤10 mm.
methodsA randomized noninferiority trial comparing mEMR-C and ESD was conducted. The primary outcome was the histological complete resection rate; the secondary outcomes included en bloc resection rate, operation time, complications, and so on. Subgroup analyses and follow-up were also performed.
resultsNinety patients were enrolled, and 79 patients with pathologically confirmed rectal NET were finally analyzed, including 38 cases of mEMR-C and 41 cases of ESD. Histological complete resection rate was 97.4% in the mEMR-C group and 92.7% in the ESD group. The noninferiority of mEMR-C compared with that of ESD was confirmed because the absolute difference was 4.7% (2-sided 90% confidence interval, -3.3% to 12.2%; P = 0.616). En bloc resection and successful removal of rectal NET were achieved in all patients. Advantages of mEMR-C over ESD included shorter operation time (8.89 ± 4.58 vs 24.8 ± 9.14 minutes, P < 0.05) and lower hospitalization cost ($2,233.76 ± $717.70 vs $2,987.27 ± $871.81, P < 0.05). Postoperative complications were recorded in 4 patients who received mEMR-C and 2 patients in the ESD group (11.5% vs 4.9%, P = 0.509), which were all well managed using endoscopy. Similar findings were observed when subgroup analysis was performed. DISCUSSION: mEMR-C is noninferior to ESD with a similar complete resection rate. In addition, mEMR-C had shorter procedure duration time and lower hospitalization costs.
trial registrationClinicalTrials.gov Identifier: NCT03982264.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.